845866-56-0

Basic information

• Product Name: 3-BROMO-4-FLUOROBENZAMIDOXIME
• Synonyms: 3-BROMO-4-FLUOROBENZAMIDOXIME
• CAS NO: 845866-56-0
• Molecular Formula: C₇H₆BrFN₂O
• Molecular Weight: 233.04
• Mol File: 845866-56-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 82-90°C
• Appearance: /
• CAS DataBase Reference: 3-BROMO-4-FLUOROBENZAMIDOXIME(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-FLUOROBENZAMIDOXIME(845866-56-0)
• EPA Substance Registry System: 3-BROMO-4-FLUOROBENZAMIDOXIME(845866-56-0)

Safety Data

• Hazardous Substances Data: 845866-56-0(Hazardous Substances Data)

Upstream product

• 79630-23-2 3-bromo-4-fluorobenzonitrile 

Downstream Products

• 1260021-99-5 5-[3-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 

Relevant articles and documents

Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1

Tryptophan metabolism through the kynurenine pathway is considered as a crucial mechanism in immune tolerance. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway. In this study, a series of nitrobenzofurazan derivatives of N′-hydroxybenzimidamides (1) and N′-hydroxy-2-phenylacetimidamides (2) were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay. The optimization leads to the identification of potent compounds, 1d, 2i and 2k (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme. These compounds also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amount of cytotoxicity. The stronger selectivity of the potent compounds for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.

2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1-isoxazolyl, R1-oxadiazolyl, R1-dihydrofuranyl, R1-pyrazolyl, R1-imidazolyl, R1-pyrazinyl or R1-pyrimidinyl; R1 is 1, 2 or 3 substituents selected from H, alkyl, alkoxy and halo; Z is optionally substituted-aryl, or optionally substituted-heteroaryl; are disclosed, as well as their use in the treatment of central nervous system diseases, in particular Parkinson's disease and Extra Pyramidal Syndrome, pharmaceutical compositions comprising them, and combinations with other agents.